Citizens Jmp Issues Positive Forecast for National Research (NASDAQ:NRC) Stock Price

National Research (NASDAQ:NRC) had its price target lifted by equities research analysts at Citizens Jmp from $23.00 to $26.00 in a note issued to investors on Wednesday,Benzinga reports. The brokerage presently has a “market outperform” rating on the stock. Citizens Jmp’s price target would suggest a potential upside of 22.27% from the company’s previous close.

Separately, Weiss Ratings raised shares of National Research from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Friday, May 29th. One research analyst has rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, National Research currently has a consensus rating of “Moderate Buy” and a consensus target price of $26.00.

National Research Stock Performance

Shares of NASDAQ NRC traded down $1.07 during midday trading on Wednesday, reaching $21.27. 22,960 shares of the company traded hands, compared to its average volume of 108,450. The company has a market cap of $483.78 million, a price-to-earnings ratio of 55.82 and a beta of 0.35. The stock has a 50-day moving average price of $20.45 and a 200 day moving average price of $18.33. National Research has a 52 week low of $11.01 and a 52 week high of $23.68. The company has a debt-to-equity ratio of 5.48, a current ratio of 0.52 and a quick ratio of 0.52.

National Research (NASDAQ:NRC) last announced its earnings results on Tuesday, July 28th. The company reported $0.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.46. The firm had revenue of $35.39 million during the quarter, compared to analyst estimates of $34.90 million. National Research had a net margin of 6.52% and a return on equity of 122.73%.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Cubist Systematic Strategies LLC acquired a new stake in shares of National Research during the 1st quarter valued at $118,000. AQR Capital Management LLC grew its holdings in shares of National Research by 168.6% in the 1st quarter. AQR Capital Management LLC now owns 108,134 shares of the company’s stock worth $1,384,000 after acquiring an additional 67,882 shares during the last quarter. Jane Street Group LLC grew its holdings in shares of National Research by 394.2% in the 1st quarter. Jane Street Group LLC now owns 52,411 shares of the company’s stock worth $671,000 after acquiring an additional 41,806 shares during the last quarter. Strs Ohio acquired a new stake in shares of National Research during the first quarter worth $33,000. Finally, M&T Bank Corp lifted its stake in National Research by 6.4% during the second quarter. M&T Bank Corp now owns 13,608 shares of the company’s stock valued at $229,000 after buying an additional 823 shares in the last quarter. Institutional investors own 47.26% of the company’s stock.

About National Research

National Research Corp (NASDAQ: NRC), also known as NRC Health, is a healthcare analytics and performance improvement company specializing in patient and employee experience measurement. The company’s cloud-based platform enables healthcare providers to collect real-time feedback through patient satisfaction surveys, post-discharge outreach, and employee engagement tools. NRC Health integrates clinical, operational and financial data to deliver actionable insights that support quality improvement initiatives and value-based care programs.

Since its founding in the early 1990s and headquartered in Lincoln, Nebraska, National Research has expanded beyond its regional roots to serve more than 1,600 hospitals and 12,000 care sites across the United States and Canada.